Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SiB-2121
- Development stage
- Preclinical
- Lead developer
- Signadori Bio
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
SiB-2121 is an experimental *in vivo* monocyte immunotherapy being developed by Signadori Bio for the treatment of solid tumors. It is part of a platform designed to engineer monocytes directly within the body to modulate monocyte-driven anti-tumor immune responses. The therapy specifically targets p21 (encoded by the *CDKN1A* gene) along with an undisclosed third target (Target 3). By modulating p21, the therapy aims to alter the functional state of monocytes and macrophages within the tumor microenvironment to promote an anti-tumor phenotype and overcome immune evasion. As of early 2024, SiB-2121 is in the discovery stage of development.
Beyond the preview
Go deeper on SiB-2121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SiB-2121.